102 related articles for article (PubMed ID: 20443766)
1. Anaemia in CKD-treatment standard.
Macdougall IC
Nephrol Dial Transplant; 2024 Apr; 39(5):770-777. PubMed ID: 38012124
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia.
Thilly N; Stengel B; Boini S; Villar E; Couchoud C; Frimat L
Nephron Clin Pract; 2008; 108(1):c67-74. PubMed ID: 18182782
[TBL] [Abstract][Full Text] [Related]
3. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes.
Dore DD; Swaminathan S; Gutman R; Trivedi AN; Mor V
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S42-50. PubMed ID: 23849152
[TBL] [Abstract][Full Text] [Related]
4. The effect of erythropoiesis-stimulating agents on systolic and diastolic blood pressure in hemodialysis patients: A systematic review and meta-analysis of clinical trials.
Karimi Z; Raeisi Shahraki H; Mohammadian-Hafshejani A
Med Clin (Barc); 2024 May; 162(10):e43-e51. PubMed ID: 38433073
[TBL] [Abstract][Full Text] [Related]
5. Tibial Lead Levels and Erythropoiesis Stimulating Agent Dosing among 75 Patients with End-Stage Kidney Disease.
Nissaisorakarn V; Specht A; Danziger J
Environ Health Perspect; 2024 Apr; 132(4):47702. PubMed ID: 38683746
[No Abstract] [Full Text] [Related]
6. Anæmia of Obscure Origin.
East T
Proc R Soc Med; 1928 Nov; 22(1):1-2. PubMed ID: 19986695
[No Abstract] [Full Text] [Related]
7. Physiology and pharmacology of erythropoietin.
Jelkmann W
Transfus Med Hemother; 2013 Oct; 40(5):302-9. PubMed ID: 24273483
[TBL] [Abstract][Full Text] [Related]
8. Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis.
Wang S; Zhou Z; Xu C; Chen H; Ren W; Yang X; Yin Q; Zheng W; Pan H
BMC Gastroenterol; 2023 Jan; 23(1):1. PubMed ID: 36593456
[TBL] [Abstract][Full Text] [Related]
9. Does Anemia Have a Potential Effect on Type 2 Hepatorenal Syndrome?
Bizid S; Yacoub H; Mohamed G; Ben Slimane B; Boughoula K; Ben Abdallah H; Bouali R; Abedelli N
Can J Gastroenterol Hepatol; 2020; 2020():1134744. PubMed ID: 33381474
[No Abstract] [Full Text] [Related]
10. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.
Valent P; Büsche G; Theurl I; Uras IZ; Germing U; Stauder R; Sotlar K; Füreder W; Bettelheim P; Pfeilstöcker M; Oberbauer R; Sperr WR; Geissler K; Schwaller J; Moriggl R; Béné MC; Jäger U; Horny HP; Hermine O
Haematologica; 2018 Oct; 103(10):1593-1603. PubMed ID: 30076180
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost.
Sagheb MM; Fallahzadeh MA; Moaref A; Fallahzadeh MH; Dormanesh B
Nephrourol Mon; 2016 Jul; 8(4):e38495. PubMed ID: 27713870
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Sahebkar A; Hassanzadeh A; Khosroshahi HT; Azar SA; Safa J; Hashemi SR; Etemadi J; Marzony ET; Noshad H
Saudi Pharm J; 2015 Oct; 23(5):544-8. PubMed ID: 26594121
[TBL] [Abstract][Full Text] [Related]
13. Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis.
Anderson ER; Xue X; Shah YM
J Biol Chem; 2011 Jun; 286(22):19533-40. PubMed ID: 21498508
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis stimulating agents and anaemia of end-stage renal disease.
Schmid H; Schiffl H
Cardiovasc Hematol Agents Med Chem; 2010 Jul; 8(3):164-72. PubMed ID: 20443766
[TBL] [Abstract][Full Text] [Related]
15. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
16. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
Coronado Daza J; Martí-Carvajal AJ; Ariza García A; Rodelo Ceballos J; Yomayusa González N; Páez-Canro C; Loza Munárriz C; Urrútia G
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011122. PubMed ID: 26671531
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
[TBL] [Abstract][Full Text] [Related]
19. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
